The Coronary Artery Calcium Score: What it is, Why it Matters, and Whether You Should Get One
Coronary artery calcium (CAC) scoring has gained significant traction in preventive cardiology over the last decade, and for good reason. It is relatively inexpensive, widely available, and provides a direct window into something that traditional risk calculators can only estimate: the actual burden of atherosclerotic plaque in the arteries of your heart. As a physician, I find it to be a useful tool we have for those patients who sit in that uncertain middle ground — people who may or may not benefit from starting a statin, and for whom a clearer picture of their arterial health can meaningfully change the conversation.
This piece covers where the test came from, what it actually measures, how the technology has evolved, when guidelines recommend it, and — most practically — whether it might make sense for you.
A Brief History
The CAC score was developed in 1990 by cardiologist Dr. Arthur Agatston and radiologist Dr. Warren Janowitz at Mount Sinai Medical Center in Miami Beach. Their work was heavily influenced by the groundbreaking Framingham Heart Study, but they wanted to go further- specifically, to identify which patients would benefit most from lipid-lowering therapy at a time when statins were just entering clinical use.
Their approach was straightforward: use CT imaging to scan the hearts of patients with known coronary artery disease alongside those without, and see what distinguished the two groups. The finding was striking. Calcium deposits were present in every patient with established disease or a prior heart attack, and largely absent in those without. This confirmed what they had hypothesized — that coronary calcium was a reliable marker of total plaque burden, and that quantifying it could help predict risk years before a patient might experience a cardiac event.
They published their findings in the Journal of the American College of Cardiology in 1990, introducing what would become known as the Agatston score. It remains the standard scoring method to this day.
What the Test Actually Measures
A CAC scan is a non-contrast CT of the heart that detects calcified deposits within the walls of the coronary arteries. No dye is injected, and the scan itself takes only a few minutes. What the radiologist is looking for are calcium deposits within atherosclerotic plaques — the same plaques that, when they rupture, cause most heart attacks.
The Agatston score is calculated by summing the calcium burden across all the major coronary arteries, with each deposit weighted for both its total area and its density. Higher density deposits receive a higher weight in the calculation. The result is a single number that reflects total plaque burden.
Scores are generally interpreted as follows:
0 — No detectable calcium. This is the most reassuring result possible, and in the absence of high-risk features like active smoking or a strong family history, is associated with a very low 10-year event rate. This is often called "the power of zero."
1–99 — Mild calcification, indicating early subclinical atherosclerosis. Risk is elevated relative to a score of zero, but the degree of intervention warranted depends on the overall clinical picture.
100–399 — Moderate calcification. This range is generally considered a clear indication for statin therapy and more aggressive lifestyle intervention.
≥400 — Extensive calcification, reflecting a high burden of coronary atherosclerosis and a meaningfully elevated risk of future events.
Importantly, a score is also interpreted in the context of age, sex, and ethnicity. A score of 50 in a 45-year-old is a very different finding than the same score in a 72-year-old. Tools like the MESA CAC Calculator allow clinicians to place any individual score into a percentile relative to their demographic peers, which can meaningfully refine how we counsel patients.
How the Technology Has Evolved: A Significant Reduction in Radiation
The original 1990 methodology used electron-beam CT (EBCT) — a specialized, expensive scanner with no moving parts, capable of freezing the motion of the beating heart with extraordinary speed. These machines were accurate, but they were extremely costly, and as such were found only at major academic centers and thus not widely available to the general public.
When multidetector CT (MDCT) proved capable of producing equivalent results, the test became dramatically more accessible (this is the CT standard found in hospitals and imaging centers all over the country today). The trade-off was a modest initial increase in radiation exposure: EBCT delivered approximately 0.7–1.3 mSv (millisieverts) depending on patient sex/body habitus, while early MDCT protocols ran slightly higher at 1.0–1.9 mSv.
Since then, however, the technological story has been one of consistent, meaningful dose reduction:
Prospective ECG gating (synchronizing x-ray exposure to a specific window within each heartbeat), standardized during the MDCT era, reduced doses by roughly 75% compared to retrospective gating protocols.
Iterative reconstruction algorithms, introduced through the 2010s, allowed the scanner to use lower radiation levels while computationally compensating for the resulting image noise. Studies showed dose reductions of 60–80% compared to older filtered back projection methods, bringing many protocols well below 0.5 mSv per scan.
AI-powered deep learning image reconstruction, the current frontier, has pushed doses into genuinely ultralow territory. Recent studies have demonstrated accurate calcium scoring at doses as low as 0.09–0.17 mSv — a tenfold or greater reduction from the original EBCT era — with no meaningful difference in score accuracy or risk categorization.
To put these numbers in perspective: the original 1 mSv exposure was roughly equivalent to 50 chest X-rays, 2.5 mammograms, 25 round-trip flights from New York to Los Angeles, or about 12 weeks of normal background radiation from simply existing on Earth. Today's optimized protocols, at around 0.1 mSv, bring that down to the equivalent of just 5 chest X-rays, less than 2 weeks of background radiation, or about one-quarter of a single mammogram.
For additional context: a routine abdomen and pelvis CT ordered in any emergency room delivers approximately 8–10 mSv. The modern calcium score, approaching 0.1 mSv, is now 80 to 100 times lower in radiation dose than that commonplace study. As a tool that can be recommended without meaningful radiation concern, it has arguably never been in a stronger position.
When Guidelines Recommend It
Despite three decades of accumulating evidence, formal endorsement by major cardiovascular bodies was a long time coming. The landmark moment arrived with the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, followed by the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, both of which gave CAC scoring a Class IIa recommendation — meaning it is reasonable to use when the decision about starting a statin remains genuinely uncertain.
The specific population the guidelines target: adults between 40 and 75 years of age, without diabetes, with LDL cholesterol ≥70 mg/dL, and an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 7.5–19.9% — the so-called intermediate-risk group. For these patients, when a clinician and patient are genuinely uncertain whether to initiate statin therapy, a CAC score can move the conversation decisively in one direction or the other.
The guidelines also formalized what to do with the result. A score of zero, in the absence of high-risk features like active smoking or a family history of premature heart disease, supports withholding statin therapy and repeating the scan in five years. A score of 100 or above, or a score at or above the 75th percentile for the patient's age, sex, and ethnicity, supports initiating statin therapy even when traditional risk calculators might have left the question open.
It is worth noting that while the CAC score has proven to be a more accurate predictor of cardiovascular events than traditional risk calculators alone, we are still awaiting high-quality randomized trial data demonstrating that CAC-guided decision making actually reduces heart attacks compared to standard risk-based management. Two ongoing trials — ROBINSCA and CorCal — are designed to answer exactly this question, and we await the results with interest.
Should You Get the Test?
As with most things in medicine, the answer depends on your individual situation — which is why the conversation should start with your physician. That said, here is a practical framework for thinking about who is likely to benefit most:
CAC scoring tends to be most useful when you fall in the intermediate cardiovascular risk range and the statin question is genuinely unresolved. Several factors may push a clinician toward recommending the test:
Age between 40 and 75, which is the primary window supported by current evidence and guidelines.
A family history of premature coronary artery disease — a first-degree relative with heart disease before age 55 in men or 65 in women — which may warrant consideration even at younger ages or lower calculated risk levels.
Uncertainty or hesitancy about starting a statin — either on the patient's part or the clinician's. A concrete score often resolves what abstract risk percentages cannot.
Prior statin intolerance, where knowing whether significant subclinical disease is present may inform how aggressively to pursue alternative lipid-lowering strategies.
On the other side of the token- patients with already established cardiovascular disease (prior heart attack, stroke, peripheral arterial disease) do not need calcium scoring for risk stratification. They are already high risk, and treatment is indicated regardless. Similarly, very low-risk individuals where the clinical picture is already clear, and those under 40 without compelling risk factors, are generally not current candidates.
At most centers, the out-of-pocket cost is in the range of $100–$200 and the scan itself takes less than 15 minutes with no preparation required. Most insurance plans do not yet cover it routinely, which remains a barrier worth acknowledging — and one that advocates in the field are actively working to address.
The bottom line: if you are in the intermediate-risk zone and you and your doctor are genuinely unsure whether preventive medication is warranted, a coronary calcium score is one of the most actionable, lowest-risk, and cost-effective pieces of information you can add to that conversation. A score of zero may allow you to safely avoid a medication you don't need. A high score may prompt treatment that prevents a heart attack you would not have seen coming.
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832. https://doi.org/10.1016/0735-1097(90)90282-T
Schmermund A. The Agatston calcium score: a milestone in the history of cardiac CT. J Cardiovasc Comput Tomogr. 2014;8(6):414–417. https://doi.org/10.1016/j.jcct.2014.09.004
Blaha MJ, Mortensen MB, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M. Coronary artery calcium scoring: is it time for a change in methodology? JACC Cardiovasc Imaging. 2017;10(8):923–937. https://doi.org/10.1016/j.jcmg.2017.05.007
Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345. https://doi.org/10.1056/NEJMoa072100
Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849–858. https://doi.org/10.1161/CIRCULATIONAHA.115.018524
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–447. https://doi.org/10.1016/j.jacc.2018.05.022
McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA with validation in the HNR and DHS studies. J Am Coll Cardiol. 2015;66(15):1643–1653. https://doi.org/10.1016/j.jacc.2015.08.035
Husain N, Bhatt DL. Radiation dose in computed tomography of the heart. Circulation. 2003;107(6):917–922. https://doi.org/10.1161/01.CIR.0000048965.56529.C2
Baron KB, Choi AD, Chen MY. Low radiation dose calcium scoring: evidence and techniques. Curr Cardiovasc Imaging Rep. 2016;9:12. https://doi.org/10.1007/s12410-016-9373-1
Choi AD, Leifer ES, Yu JH, et al. Reduced radiation dose with model based iterative reconstruction coronary artery calcium scoring. Eur J Radiol. 2019;111:1–5. https://doi.org/10.1016/j.ejrad.2018.12.010
Xu Y, Nagel E, Bremerich J, et al. Ultralow dose coronary calcium scoring CT at reduced tube voltage and current by using deep learning image reconstruction. Eur J Radiol. 2024. https://doi.org/10.1016/j.ejrad.2024.111504
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596–e646. https://doi.org/10.1161/CIR.0000000000000678
Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–795. https://doi.org/10.1001/jama.2012.9624
Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to ACC/AHA cholesterol management guidelines: MESA. J Am Coll Cardiol. 2015;66(15):1657–1668. https://doi.org/10.1016/j.jacc.2015.08.033
Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2017;11(2):157–168. https://doi.org/10.1016/j.jcct.2017.02.010
van der Aalst CM, Van den Berg M, Van Engen-Van Grunsven IM, et al. Screening for cardiovascular disease risk with a CT-derived risk score vs the ESC risk score: rationale and design of the ROBINSCA trial. Am Heart J. 2019;213:72–81. https://doi.org/10.1016/j.ahj.2019.03.011
